Cassava Sciences Stock Slumps After Alzheimer's Trial Miss
Cassava Sciences Inc.'s (SAVA) stock crashed as the company reported topline data from its mid-stage trial of its Alzheimer’s drug candidate. The Phase 2b study aimed to assess the potential of PTI-125 in treating patients suffering from Alzheimer’s. The trial failed to meet its primary endpoint of significant impact on cerebrospinal fluid levels. However, it succeeded in meeting a secondary endpoint of reducing CSF levels of another important biomarker IL1-beta.
The Phase 2b study was a double-blind randomized placebo-controlled trial and involved 64 patients with